HOOKIPA Pharma Inc. (Nasdaq: HOOK) has released promising preliminary data from its Phase 2 study of HB-200 in combination with pembrolizumab, offering hope for patients with recurrent/metastatic Human Papillomavirus 16-positive (HPV16+) head and neck cancer. 

The new data showed an impressive 43 percent objective response rate (ORR) in CPI-naïve patients, effectively doubling the 19 percent response rate observed with pembrolizumab alone. 

This is a significant development, considering that HPV, a common viral infection, is responsible for up to 60 percent of head and neck cancer cases worldwide. 

Following the announcement, $HOOK experienced a notable surge in after-hours trading, reaching $1.73 with a substantial increase of $0.42 (+32.06%).

In other news, Chewy, Inc. (NYSE: CHWY) has reported strong performance in the first quarter of fiscal 2023, exceeding market expectations. 

The company achieved an adjusted earnings per share (EPS) of $0.20, surpassing the consensus estimate of a loss of $0.04 per share. Chewy's impressive Q1 results reflect a remarkable acceleration in double-digit topline growth and continued expansion of their adjusted EBITDA margin. 

As a result, $CHWY experienced a significant boost in after-hours trading, reaching $33.38, with a notable increase of $3.89 or 13.19%.

On the other hand, C3.ai, Inc. (NYSE: AI) has reported a loss of $0.13 per share for the fourth quarter of fiscal 2023, slightly better than the consensus estimate loss of $0.17 per share. 

Looking ahead, C3.ai expects its full-year fiscal 2024 revenue to range between $295 million and $320 million, deviating slightly from the consensus estimate of $317.07 million. However, the company remains committed to its profitability plan, aiming to achieve a sustainably non-GAAP profitable business by the end of fiscal year 2024, which concludes on April 30, 2024. 

In after-hours trading, $AI experienced a decline, reaching $31.31 with a notable decrease of $8.70 or 21.74%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)